| About the Author: | Ram I. Mahato is a full time Professor of Pharmaceutics and Drug Delivery at the Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis. Dr. Mahato has served as a Research Assistant Professor at the University of Utah; and Senior Scientist at GeneMedicine, Inc.; and as a postdoctoral fellow at the University of Southern California, Washington University and Kyoto University. He received Ph.D. in Pharmaceutics and Drug Delivery from the University of Strathclyde (Glasgow, Great Britain) in 1992. He has two issued United States patents and is author or co-authors of more than 90 papers and book chapters. He has edited six journal theme issues, four books and written one textbook. He is a Theme Issue Editor for Pharmaceutical Research and a member of the editorial board of seven journals. He is an AAPS Fellow and regular member of the BTSS Study section of the National Institutes of Health. His research includes delivery and targeting of small molecules, oligonucleotides, siRNA and genes. Ajit S. Narang works for the Drug Product Science & Technology Department of Bristol-Myers Squibb, Co. (BMS) in New Brunswick, NJ. His primary expertise is in oral drug delivery. He holds over 9 years of pharmaceutical industry experience in the development of oral dosage forms and drug delivery platforms. In addition to BMS, he has worked for Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) and Morton Grove Pharmaceuticals (currently, Wockhardt USA). He holds undergraduate Pharmacy degree from the University of Delhi, India and graduate degrees in Pharmaceutical Sciences from the Banaras Hindu University, India and the University of Tennessee Health Science Center (UTHSC) in Memphis, TN. He currently serves the Excipient Focus Group chair-elect for the American Association of Pharmaceutical Scientists (AAPS), Adjunct Faculty for the UTHSC, and Associate Faculty for the University of Phoenix, AZ. His current research interests include innovations in dosage form development and drug delivery technologies that enable pharmaceutical development of challenging molecules to resolve stability, pharmacokinetic, and pharmacodynamic issues. He has more than 40 publications and three pending patent applications, and has contributed to the development of several marketed drug products. |
|---|
/yaootaweb-production-sa/media/crawledproductimages/6f407a01c37aff7b28dabcc9d1eece2b26b04151.jpg)